Genetics Generation Advancement（4160）株式概要Genetics Generation Advancement Corp.は台湾で遺伝子検査とインフォマティクスサービスを提供している。 詳細4160 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績2/6財務の健全性5/6配当金1/6リスク分析4.44%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない 意味のある時価総額がありません ( NT$1B )利益率(2.3%)は昨年より低い(7.5%) すべてのリスクチェックを見る4160 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,690 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG490,690 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$41.650.02% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-16m796m2016201920222025202620282031Revenue NT$795.6mEarnings NT$18.1mAdvancedSet Fair ValueView all narrativesGenetics Generation Advancement Corp. 競合他社Taiwan Advance Bio-PharmaceuticalSymbol: TPEX:4186Market cap: NT$891.9mGenMont Biotech IncorporationSymbol: TWSE:3164Market cap: NT$1.4bSynbio TechSymbol: TPEX:1295Market cap: NT$1.7bBioray BiotechSymbol: TPEX:7561Market cap: NT$563.6m価格と性能株価の高値、安値、推移の概要Genetics Generation Advancement過去の株価現在の株価NT$41.6552週高値NT$60.5052週安値NT$39.05ベータ0.341ヶ月の変化3.87%3ヶ月変化-8.46%1年変化-15.86%3年間の変化23.08%5年間の変化88.28%IPOからの変化-0.92%最新ニュースBoard Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Independent Director Pui Kwan Chan was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.80 (vs NT$2.05 in FY 2024)Full year 2025 results: EPS: NT$0.80 (down from NT$2.05 in FY 2024). Revenue: NT$603.1m (down 8.9% from FY 2024). Net income: NT$21.4m (down 61% from FY 2024). Profit margin: 3.5% (down from 8.3% in FY 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 03Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026. Location: 6-5 floor no,28 ln.78, hsing ai rd., neihu district, taipei city TaiwanBuy Or Sell Opportunity • Jan 14Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.4% to NT$54.80. The fair value is estimated to be NT$45.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has grown by 17%.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: NT$0.02 (vs NT$0.72 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.02 (down from NT$0.72 in 3Q 2024). Revenue: NT$145.5m (down 14% from 3Q 2024). Net income: NT$454.0k (down 98% from 3Q 2024). Profit margin: 0.3% (down from 11% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Sep 26Upcoming dividend of NT$1.85 per shareEligible shareholders must have bought the stock before 03 October 2025. Payment date: 31 October 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.0%).最新情報をもっと見るRecent updatesBoard Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Independent Director Pui Kwan Chan was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.80 (vs NT$2.05 in FY 2024)Full year 2025 results: EPS: NT$0.80 (down from NT$2.05 in FY 2024). Revenue: NT$603.1m (down 8.9% from FY 2024). Net income: NT$21.4m (down 61% from FY 2024). Profit margin: 3.5% (down from 8.3% in FY 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 03Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026. Location: 6-5 floor no,28 ln.78, hsing ai rd., neihu district, taipei city TaiwanBuy Or Sell Opportunity • Jan 14Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.4% to NT$54.80. The fair value is estimated to be NT$45.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has grown by 17%.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: NT$0.02 (vs NT$0.72 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.02 (down from NT$0.72 in 3Q 2024). Revenue: NT$145.5m (down 14% from 3Q 2024). Net income: NT$454.0k (down 98% from 3Q 2024). Profit margin: 0.3% (down from 11% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Sep 26Upcoming dividend of NT$1.85 per shareEligible shareholders must have bought the stock before 03 October 2025. Payment date: 31 October 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.0%).New Risk • Sep 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 154% Cash payout ratio: 137% Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (NT$1.58b market cap, or US$52.1m).Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: NT$0.08 (vs NT$0.68 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.08 (down from NT$0.68 in 2Q 2024). Revenue: NT$145.1m (down 14% from 2Q 2024). Net income: NT$2.16m (down 88% from 2Q 2024). Profit margin: 1.5% (down from 11% in 2Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 34% per year and the company’s share price has also increased by 34% per year.Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$59.50, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 31x in the Biotechs industry in Taiwan. Total returns to shareholders of 181% over the past three years.Reported Earnings • May 18First quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.53 in 1Q 2024)First quarter 2025 results: EPS: NT$0.29 (down from NT$0.53 in 1Q 2024). Revenue: NT$143.4m (down 14% from 1Q 2024). Net income: NT$7.65m (down 46% from 1Q 2024). Profit margin: 5.3% (down from 8.5% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.New Risk • Apr 10New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. Payout ratio: 90% Dividend yield: 3.5% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (90% payout ratio). Market cap is less than US$100m (NT$1.27b market cap, or US$38.6m).Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$52.10, the stock trades at a trailing P/E ratio of 25.4x. Average trailing P/E is 28x in the Biotechs industry in Taiwan. Total returns to shareholders of 138% over the past three years.Reported Earnings • Mar 30Full year 2024 earnings released: EPS: NT$2.05 (vs NT$1.07 in FY 2023)Full year 2024 results: EPS: NT$2.05 (up from NT$1.07 in FY 2023). Revenue: NT$661.9m (up 12% from FY 2023). Net income: NT$54.7m (up 92% from FY 2023). Profit margin: 8.3% (up from 4.8% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year whereas the company’s share price has increased by 46% per year.お知らせ • Mar 11Genetics Generation Advancement Corp., Annual General Meeting, Jun 13, 2025Genetics Generation Advancement Corp., Annual General Meeting, Jun 13, 2025. Location: 6-5 floor no,28 ln.78, hsing ai rd., neihu district, taipei city TaiwanNew Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (NT$2.36b market cap, or US$73.0m).Reported Earnings • Nov 19Third quarter 2024 earnings released: EPS: NT$0.72 (vs NT$0.18 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.72 (up from NT$0.18 in 3Q 2023). Revenue: NT$170.2m (up 9.9% from 3Q 2023). Net income: NT$19.2m (up 294% from 3Q 2023). Profit margin: 11% (up from 3.2% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 57% per year whereas the company’s share price has increased by 53% per year.Upcoming Dividend • Sep 12Upcoming dividend of NT$0.51 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 25 October 2024. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Taiwanese dividend payers (4.5%). Lower than average of industry peers (2.7%).Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.72 (vs NT$0.37 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.72 (up from NT$0.37 in 2Q 2023). Revenue: NT$169.6m (up 17% from 2Q 2023). Net income: NT$18.2m (up 95% from 2Q 2023). Profit margin: 11% (up from 6.4% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year and the company’s share price has also increased by 65% per year.Declared Dividend • Aug 09Dividend of NT$0.51 announcedShareholders will receive a dividend of NT$0.51. Ex-date: 19th September 2024 Payment date: 25th October 2024 Dividend yield will be 0.5%, which is lower than the industry average of 2.6%. Payout Ratios Payout ratio: 37%. Cash payout ratio: 23%.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$109, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 375% over the past three years.Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$110, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 43x in the Biotechs industry in Taiwan. Total returns to shareholders of 373% over the past three years.Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 29%After last week's 29% share price gain to NT$97.50, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 339% over the past three years.Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$68.00, the stock trades at a trailing P/E ratio of 49x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 213% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.56 (vs NT$0.29 in 1Q 2023)First quarter 2024 results: EPS: NT$0.56 (up from NT$0.29 in 1Q 2023). Revenue: NT$166.9m (up 24% from 1Q 2023). Net income: NT$14.2m (up 90% from 1Q 2023). Profit margin: 8.5% (up from 5.6% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$50.50, the stock trades at a trailing P/E ratio of 44.9x. Average trailing P/E is 47x in the Biotechs industry in Taiwan. Total returns to shareholders of 117% over the past three years.お知らせ • Mar 31Genetics Generation Advancement Corp., Annual General Meeting, Jun 18, 2024Genetics Generation Advancement Corp., Annual General Meeting, Jun 18, 2024.Reported Earnings • Mar 28Full year 2023 earnings released: EPS: NT$1.12 (vs NT$1.01 in FY 2022)Full year 2023 results: EPS: NT$1.12 (up from NT$1.01 in FY 2022). Revenue: NT$592.5m (up 8.2% from FY 2022). Net income: NT$28.6m (up 11% from FY 2022). Profit margin: 4.8% (up from 4.7% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$0.19 (vs NT$0.31 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.19 (down from NT$0.31 in 3Q 2022). Revenue: NT$154.8m (up 17% from 3Q 2022). Net income: NT$4.88m (down 38% from 3Q 2022). Profit margin: 3.2% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Sep 07Upcoming dividend of NT$0.48 per share at 1.1% yieldEligible shareholders must have bought the stock before 14 September 2023. Payment date: 20 October 2023. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (2.7%).Reported Earnings • Aug 10Second quarter 2023 earnings released: EPS: NT$0.38 (vs NT$0.036 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.38 (up from NT$0.036 in 2Q 2022). Revenue: NT$145.4m (up 8.3% from 2Q 2022). Net income: NT$9.31m (up NT$8.44m from 2Q 2022). Profit margin: 6.4% (up from 0.6% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$47.90, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 50x in the Biotechs industry in Taiwan. Total returns to shareholders of 74% over the past three years.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$44.00, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 45x in the Biotechs industry in Taiwan. Total returns to shareholders of 51% over the past three years.Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$35.25, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 41x in the Biotechs industry in Taiwan. Total returns to shareholders of 40% over the past three years.Board Change • Jan 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Director Yu Min Liang was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$28.60, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 35x in the Biotechs industry in Taiwan. Total returns to shareholders of 5.0% over the past three years.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: NT$0.32 (vs NT$0.15 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.32 (up from NT$0.15 in 3Q 2021). Revenue: NT$132.4m (down 3.3% from 3Q 2021). Net income: NT$7.83m (up 122% from 3Q 2021). Profit margin: 5.9% (up from 2.6% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Upcoming Dividend • Aug 29Upcoming dividend of NT$0.29 per shareEligible shareholders must have bought the stock before 05 September 2022. Payment date: 30 September 2022. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (6.4%). Lower than average of industry peers (2.2%).お知らせ • Aug 16Genetics Generation Advancement Corp. Announces Cash Dividend, Payable on September 30, 2022Genetics Generation Advancement Corp. announced cash dividend of TWD 0.29097003 per share, total amount is TWD 7,055,155. Ex-rights (Ex-dividend) date: September 5, 2022. Ex-rights (Ex-dividend) record date: September 11, 2022. Payment date of cash dividend distribution: September 30, 2022.Reported Earnings • May 16First quarter 2022 earnings released: EPS: NT$0.44 (vs NT$0.019 loss in 1Q 2021)First quarter 2022 results: EPS: NT$0.44 (up from NT$0.019 loss in 1Q 2021). Revenue: NT$139.7m (up 16% from 1Q 2021). Net income: NT$10.7m (up NT$11.2m from 1Q 2021). Profit margin: 7.7% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 01Full year 2021 earnings released: EPS: NT$0.32 (vs NT$0.65 loss in FY 2020)Full year 2021 results: EPS: NT$0.32 (up from NT$0.65 loss in FY 2020). Revenue: NT$519.5m (up 17% from FY 2020). Net income: NT$7.84m (up NT$23.5m from FY 2020). Profit margin: 1.5% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS NT$0.15 (vs NT$0.19 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$137.0m (up 15% from 3Q 2020). Net income: NT$3.53m (up NT$8.08m from 3Q 2020). Profit margin: 2.6% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.096 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$140.9m (up 36% from 2Q 2020). Net income: NT$6.32m (up NT$8.65m from 2Q 2020). Profit margin: 4.5% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.Reported Earnings • May 17First quarter 2021 earnings released: NT$0.02 loss per share (vs NT$0.01 profit in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: NT$120.2m (up 14% from 1Q 2020). Net loss: NT$463.0k (down 290% from profit in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 31Full year 2020 earnings released: NT$0.65 loss per share (vs NT$0.76 profit in FY 2019)The company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: NT$443.1m (up 3.2% from FY 2019). Net loss: NT$15.7m (down 186% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • Mar 18Genetics Generation Advancement Corp., Annual General Meeting, Jun 10, 2021Genetics Generation Advancement Corp., Annual General Meeting, Jun 10, 2021. Location: 6F.-5, No.28, Ln. 78, Xingai Rd., Neihu Dist., Taipei City 114 Taiwan Taiwan Agenda: To consider 2020 Annual Business Report; to consider audit Committee's 2020 Review Report; and to consider withdrawal for a cash offering by private placement proposed on the 2020.分析記事 • Feb 25Consider This Before Buying Genetics Generation Advancement Corp. (GTSM:4160) For The 2.8% DividendIs Genetics Generation Advancement Corp. ( GTSM:4160 ) a good dividend stock? How can we tell? Dividend paying...Is New 90 Day High Low • Feb 04New 90-day low: NT$23.05The company is down 6.0% from its price of NT$24.50 on 06 November 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 6.0% over the same period.Is New 90 Day High Low • Jan 20New 90-day low: NT$23.10The company is down 6.0% from its price of NT$24.55 on 23 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Dec 28New 90-day high: NT$25.50The company is up 2.0% from its price of NT$25.05 on 30 September 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period.Is New 90 Day High Low • Dec 09New 90-day low: NT$24.00The company is down 7.0% from its price of NT$25.70 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.19 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: NT$118.8m (up 14% from 3Q 2019). Net loss: NT$4.55m (loss widened NT$4.49m from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Nov 12New 90-day low: NT$24.20The company is down 16% from its price of NT$28.80 on 14 August 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.株主還元4160TW BiotechsTW 市場7D2.7%3.9%-3.1%1Y-15.9%86.2%97.8%株主還元を見る業界別リターン: 4160過去 1 年間で86.2 % の収益を上げたTW Biotechs業界を下回りました。リターン対市場: 4160は、過去 1 年間で97.8 % のリターンを上げたTW市場を下回りました。価格変動Is 4160's price volatile compared to industry and market?4160 volatility4160 Average Weekly Movement3.9%Biotechs Industry Average Movement6.3%Market Average Movement6.5%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.6%安定した株価: 4160 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4160の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2008n/aQing Yuan Kangwww.gga.asiaGenetics Generation Advancement Corp.は台湾で遺伝子検査と情報学サービスを提供している。着床前検査、出生前検査、新生児検診、健康管理、生殖医療検査、産婦人科検査、新生児・小児科検査などの検査サービスや、消化器、肝臓、腫瘍、医療研究サービスを提供。また、ライフサイエンス、マテリアルサイエンス、研究開発管理、企業品質管理、プロセス生産オペレーション、電子申請製品も提供している。以前はジェネシス・ジェネティクス・アジア社として知られていたが、2016年2月にジェネティクス・ジェネレーション・アドバンスメント社に社名変更した。Genetics Generation Advancement Corp.は2008年に設立され、台湾の台北市に拠点を置いている。もっと見るGenetics Generation Advancement Corp. 基礎のまとめGenetics Generation Advancement の収益と売上を時価総額と比較するとどうか。4160 基礎統計学時価総額NT$1.11b収益（TTM）NT$13.89m売上高(TTM)NT$609.13m80.0xPER（株価収益率1.8xP/Sレシオ4160 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4160 損益計算書（TTM）収益NT$609.13m売上原価NT$359.20m売上総利益NT$249.93mその他の費用NT$236.04m収益NT$13.89m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.52グロス・マージン41.03%純利益率2.28%有利子負債／自己資本比率17.5%4160 の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.4%現在の配当利回り369%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/10 20:24終値2026/07/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genetics Generation Advancement Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Independent Director Pui Kwan Chan was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.80 (vs NT$2.05 in FY 2024)Full year 2025 results: EPS: NT$0.80 (down from NT$2.05 in FY 2024). Revenue: NT$603.1m (down 8.9% from FY 2024). Net income: NT$21.4m (down 61% from FY 2024). Profit margin: 3.5% (down from 8.3% in FY 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 03Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026. Location: 6-5 floor no,28 ln.78, hsing ai rd., neihu district, taipei city Taiwan
Buy Or Sell Opportunity • Jan 14Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.4% to NT$54.80. The fair value is estimated to be NT$45.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has grown by 17%.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: NT$0.02 (vs NT$0.72 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.02 (down from NT$0.72 in 3Q 2024). Revenue: NT$145.5m (down 14% from 3Q 2024). Net income: NT$454.0k (down 98% from 3Q 2024). Profit margin: 0.3% (down from 11% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Sep 26Upcoming dividend of NT$1.85 per shareEligible shareholders must have bought the stock before 03 October 2025. Payment date: 31 October 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.0%).
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Independent Director Pui Kwan Chan was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.80 (vs NT$2.05 in FY 2024)Full year 2025 results: EPS: NT$0.80 (down from NT$2.05 in FY 2024). Revenue: NT$603.1m (down 8.9% from FY 2024). Net income: NT$21.4m (down 61% from FY 2024). Profit margin: 3.5% (down from 8.3% in FY 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 03Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026Genetics Generation Advancement Corp., Annual General Meeting, Jun 17, 2026. Location: 6-5 floor no,28 ln.78, hsing ai rd., neihu district, taipei city Taiwan
Buy Or Sell Opportunity • Jan 14Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.4% to NT$54.80. The fair value is estimated to be NT$45.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has grown by 17%.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: NT$0.02 (vs NT$0.72 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.02 (down from NT$0.72 in 3Q 2024). Revenue: NT$145.5m (down 14% from 3Q 2024). Net income: NT$454.0k (down 98% from 3Q 2024). Profit margin: 0.3% (down from 11% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Sep 26Upcoming dividend of NT$1.85 per shareEligible shareholders must have bought the stock before 03 October 2025. Payment date: 31 October 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.0%).
New Risk • Sep 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 154% Cash payout ratio: 137% Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (NT$1.58b market cap, or US$52.1m).
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: NT$0.08 (vs NT$0.68 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.08 (down from NT$0.68 in 2Q 2024). Revenue: NT$145.1m (down 14% from 2Q 2024). Net income: NT$2.16m (down 88% from 2Q 2024). Profit margin: 1.5% (down from 11% in 2Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 34% per year and the company’s share price has also increased by 34% per year.
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$59.50, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 31x in the Biotechs industry in Taiwan. Total returns to shareholders of 181% over the past three years.
Reported Earnings • May 18First quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.53 in 1Q 2024)First quarter 2025 results: EPS: NT$0.29 (down from NT$0.53 in 1Q 2024). Revenue: NT$143.4m (down 14% from 1Q 2024). Net income: NT$7.65m (down 46% from 1Q 2024). Profit margin: 5.3% (down from 8.5% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
New Risk • Apr 10New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. Payout ratio: 90% Dividend yield: 3.5% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (90% payout ratio). Market cap is less than US$100m (NT$1.27b market cap, or US$38.6m).
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$52.10, the stock trades at a trailing P/E ratio of 25.4x. Average trailing P/E is 28x in the Biotechs industry in Taiwan. Total returns to shareholders of 138% over the past three years.
Reported Earnings • Mar 30Full year 2024 earnings released: EPS: NT$2.05 (vs NT$1.07 in FY 2023)Full year 2024 results: EPS: NT$2.05 (up from NT$1.07 in FY 2023). Revenue: NT$661.9m (up 12% from FY 2023). Net income: NT$54.7m (up 92% from FY 2023). Profit margin: 8.3% (up from 4.8% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year whereas the company’s share price has increased by 46% per year.
お知らせ • Mar 11Genetics Generation Advancement Corp., Annual General Meeting, Jun 13, 2025Genetics Generation Advancement Corp., Annual General Meeting, Jun 13, 2025. Location: 6-5 floor no,28 ln.78, hsing ai rd., neihu district, taipei city Taiwan
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (NT$2.36b market cap, or US$73.0m).
Reported Earnings • Nov 19Third quarter 2024 earnings released: EPS: NT$0.72 (vs NT$0.18 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.72 (up from NT$0.18 in 3Q 2023). Revenue: NT$170.2m (up 9.9% from 3Q 2023). Net income: NT$19.2m (up 294% from 3Q 2023). Profit margin: 11% (up from 3.2% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 57% per year whereas the company’s share price has increased by 53% per year.
Upcoming Dividend • Sep 12Upcoming dividend of NT$0.51 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 25 October 2024. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Taiwanese dividend payers (4.5%). Lower than average of industry peers (2.7%).
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.72 (vs NT$0.37 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.72 (up from NT$0.37 in 2Q 2023). Revenue: NT$169.6m (up 17% from 2Q 2023). Net income: NT$18.2m (up 95% from 2Q 2023). Profit margin: 11% (up from 6.4% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year and the company’s share price has also increased by 65% per year.
Declared Dividend • Aug 09Dividend of NT$0.51 announcedShareholders will receive a dividend of NT$0.51. Ex-date: 19th September 2024 Payment date: 25th October 2024 Dividend yield will be 0.5%, which is lower than the industry average of 2.6%. Payout Ratios Payout ratio: 37%. Cash payout ratio: 23%.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$109, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 375% over the past three years.
Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$110, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 43x in the Biotechs industry in Taiwan. Total returns to shareholders of 373% over the past three years.
Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 29%After last week's 29% share price gain to NT$97.50, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 339% over the past three years.
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$68.00, the stock trades at a trailing P/E ratio of 49x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 213% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.56 (vs NT$0.29 in 1Q 2023)First quarter 2024 results: EPS: NT$0.56 (up from NT$0.29 in 1Q 2023). Revenue: NT$166.9m (up 24% from 1Q 2023). Net income: NT$14.2m (up 90% from 1Q 2023). Profit margin: 8.5% (up from 5.6% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$50.50, the stock trades at a trailing P/E ratio of 44.9x. Average trailing P/E is 47x in the Biotechs industry in Taiwan. Total returns to shareholders of 117% over the past three years.
お知らせ • Mar 31Genetics Generation Advancement Corp., Annual General Meeting, Jun 18, 2024Genetics Generation Advancement Corp., Annual General Meeting, Jun 18, 2024.
Reported Earnings • Mar 28Full year 2023 earnings released: EPS: NT$1.12 (vs NT$1.01 in FY 2022)Full year 2023 results: EPS: NT$1.12 (up from NT$1.01 in FY 2022). Revenue: NT$592.5m (up 8.2% from FY 2022). Net income: NT$28.6m (up 11% from FY 2022). Profit margin: 4.8% (up from 4.7% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$0.19 (vs NT$0.31 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.19 (down from NT$0.31 in 3Q 2022). Revenue: NT$154.8m (up 17% from 3Q 2022). Net income: NT$4.88m (down 38% from 3Q 2022). Profit margin: 3.2% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Sep 07Upcoming dividend of NT$0.48 per share at 1.1% yieldEligible shareholders must have bought the stock before 14 September 2023. Payment date: 20 October 2023. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (2.7%).
Reported Earnings • Aug 10Second quarter 2023 earnings released: EPS: NT$0.38 (vs NT$0.036 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.38 (up from NT$0.036 in 2Q 2022). Revenue: NT$145.4m (up 8.3% from 2Q 2022). Net income: NT$9.31m (up NT$8.44m from 2Q 2022). Profit margin: 6.4% (up from 0.6% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to NT$47.90, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 50x in the Biotechs industry in Taiwan. Total returns to shareholders of 74% over the past three years.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$44.00, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 45x in the Biotechs industry in Taiwan. Total returns to shareholders of 51% over the past three years.
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$35.25, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 41x in the Biotechs industry in Taiwan. Total returns to shareholders of 40% over the past three years.
Board Change • Jan 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Director Yu Min Liang was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$28.60, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 35x in the Biotechs industry in Taiwan. Total returns to shareholders of 5.0% over the past three years.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: NT$0.32 (vs NT$0.15 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.32 (up from NT$0.15 in 3Q 2021). Revenue: NT$132.4m (down 3.3% from 3Q 2021). Net income: NT$7.83m (up 122% from 3Q 2021). Profit margin: 5.9% (up from 2.6% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Aug 29Upcoming dividend of NT$0.29 per shareEligible shareholders must have bought the stock before 05 September 2022. Payment date: 30 September 2022. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (6.4%). Lower than average of industry peers (2.2%).
お知らせ • Aug 16Genetics Generation Advancement Corp. Announces Cash Dividend, Payable on September 30, 2022Genetics Generation Advancement Corp. announced cash dividend of TWD 0.29097003 per share, total amount is TWD 7,055,155. Ex-rights (Ex-dividend) date: September 5, 2022. Ex-rights (Ex-dividend) record date: September 11, 2022. Payment date of cash dividend distribution: September 30, 2022.
Reported Earnings • May 16First quarter 2022 earnings released: EPS: NT$0.44 (vs NT$0.019 loss in 1Q 2021)First quarter 2022 results: EPS: NT$0.44 (up from NT$0.019 loss in 1Q 2021). Revenue: NT$139.7m (up 16% from 1Q 2021). Net income: NT$10.7m (up NT$11.2m from 1Q 2021). Profit margin: 7.7% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 01Full year 2021 earnings released: EPS: NT$0.32 (vs NT$0.65 loss in FY 2020)Full year 2021 results: EPS: NT$0.32 (up from NT$0.65 loss in FY 2020). Revenue: NT$519.5m (up 17% from FY 2020). Net income: NT$7.84m (up NT$23.5m from FY 2020). Profit margin: 1.5% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS NT$0.15 (vs NT$0.19 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$137.0m (up 15% from 3Q 2020). Net income: NT$3.53m (up NT$8.08m from 3Q 2020). Profit margin: 2.6% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.096 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$140.9m (up 36% from 2Q 2020). Net income: NT$6.32m (up NT$8.65m from 2Q 2020). Profit margin: 4.5% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 17First quarter 2021 earnings released: NT$0.02 loss per share (vs NT$0.01 profit in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: NT$120.2m (up 14% from 1Q 2020). Net loss: NT$463.0k (down 290% from profit in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 31Full year 2020 earnings released: NT$0.65 loss per share (vs NT$0.76 profit in FY 2019)The company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: NT$443.1m (up 3.2% from FY 2019). Net loss: NT$15.7m (down 186% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 18Genetics Generation Advancement Corp., Annual General Meeting, Jun 10, 2021Genetics Generation Advancement Corp., Annual General Meeting, Jun 10, 2021. Location: 6F.-5, No.28, Ln. 78, Xingai Rd., Neihu Dist., Taipei City 114 Taiwan Taiwan Agenda: To consider 2020 Annual Business Report; to consider audit Committee's 2020 Review Report; and to consider withdrawal for a cash offering by private placement proposed on the 2020.
分析記事 • Feb 25Consider This Before Buying Genetics Generation Advancement Corp. (GTSM:4160) For The 2.8% DividendIs Genetics Generation Advancement Corp. ( GTSM:4160 ) a good dividend stock? How can we tell? Dividend paying...
Is New 90 Day High Low • Feb 04New 90-day low: NT$23.05The company is down 6.0% from its price of NT$24.50 on 06 November 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 6.0% over the same period.
Is New 90 Day High Low • Jan 20New 90-day low: NT$23.10The company is down 6.0% from its price of NT$24.55 on 23 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Dec 28New 90-day high: NT$25.50The company is up 2.0% from its price of NT$25.05 on 30 September 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Dec 09New 90-day low: NT$24.00The company is down 7.0% from its price of NT$25.70 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.19 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: NT$118.8m (up 14% from 3Q 2019). Net loss: NT$4.55m (loss widened NT$4.49m from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Nov 12New 90-day low: NT$24.20The company is down 16% from its price of NT$28.80 on 14 August 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
